Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIIB News Highlights
- For BIIB, its 30 day story count is now at 21.
- Over the past 23 days, the trend for BIIB's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about BIIB are DRUG, DEC and HUGE.
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
12 Best Stocks to Buy for an 18 Year OldIn this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in […] |
Healthcare Heroes: 3 Stocks Innovating in Medicine and WellnessDiscover these innovative healthcare stocks, backed by the U.S.'s $4.3 trillion health investment, offering stability and high returns. |
Top 3 Healthcare Stock Picks for the New YearBuy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals. |
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA NodFDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone. |
Is Eli Lilly Stock A Buy Or A Sell As Shares Seesaw On Recent Obesity Drug Findings?Is Eli Lilly stock a buy or a sell as shares seesaw in the wake of new Zepbound test results? LLY stock a buy or a sell right now? |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to OtsukaPer the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe. |
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionCAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva. In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA. Biogen welcomes the actions of the European Com |
Biogen holds onto Tecfidera market in Europe for a little longerA decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025. |
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EUBiogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older. |